Literature DB >> 24911636

Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy.

Lin Xiang1, Guangda Xiang2, Ling Yue3, Junxia Zhang4, Linshuang Zhao5.   

Abstract

OBJECTIVE: Irisin is a newly identified myokine that can promote energy expenditure and alleviate insulin-resistance in animal model. It has been established that insulin resistance is frequently associated with endothelial dysfunction. Therefore, we hypothesize that circulating irisin levels are associated with endothelial dysfunction in type 2 diabetes.
METHODS: One hundred and eighty eight patients with newly diagnosed type 2 diabetes and 40 healthy subjects were recruited. Serum irisin concentrations were measured by using enzyme-linked immunosorbent assay, and flow-mediated dilation (FMD) was evaluated by using high-resolution ultrasound.
RESULTS: The mean value of circulating irisin levels in newly diagnosed type 2 diabetes was 13.25 ng/ml, which was significantly lower than that in controls (25.98 ng/ml, p < 0.001). By dividing the distribution of FMD levels into quartiles, serum irisin levels were increased gradually with the increase of FMD levels (p < 0.001). Multivariate stepwise regression analysis demonstrated that serum irisin levels were independently associated with FMD (p = 0.009). By logistic regression analysis the odds ratio for lower FMD levels was reduced by 11.8% per 1 ng/ml increase in serum irisin concentration after adjustment for multivariate metabolic factors [OR (95% CI); 0.882 (0.709-0.969)].
CONCLUSION: These results demonstrated that circulating irisin levels were decreased in newly diagnosed Chinese type 2 diabetic patients without clinical angiopathy and positively associated with FMD levels.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Circulating irisin; Endothelial dysfunction; Type 2 diabetes

Mesh:

Substances:

Year:  2014        PMID: 24911636     DOI: 10.1016/j.atherosclerosis.2014.04.036

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  31 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

Review 2.  The role of Irisin in multiorgan protection.

Authors:  Jun Ma; Ken Chen
Journal:  Mol Biol Rep       Date:  2021-01-03       Impact factor: 2.316

3.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

4.  Decreased irisin secretion contributes to muscle insulin resistance in high-fat diet mice.

Authors:  Zaigang Yang; Xu Chen; Yujuan Chen; Qian Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  Irisin in blood increases transiently after single sessions of intense endurance exercise and heavy strength training.

Authors:  Håvard Nygaard; Gunnar Slettaløkken; Geir Vegge; Ivana Hollan; Jon Elling Whist; Tor Strand; Bent R Rønnestad; Stian Ellefsen
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

Review 6.  Irisin and Myonectin Regulation in the Insulin Resistant Muscle: Implications to Adipose Tissue: Muscle Crosstalk.

Authors:  Luis Gamas; Paulo Matafome; Raquel Seiça
Journal:  J Diabetes Res       Date:  2015-05-05       Impact factor: 4.011

7.  Irisin evokes bradycardia by activating cardiac-projecting neurons of nucleus ambiguus.

Authors:  Eugen Brailoiu; Elena Deliu; Romeo A Sporici; G Cristina Brailoiu
Journal:  Physiol Rep       Date:  2015-06

Review 8.  Irisin: a new molecular marker and target in metabolic disorder.

Authors:  Jia-qi Chen; Yue-ye Huang; Aaron M Gusdon; Shen Qu
Journal:  Lipids Health Dis       Date:  2015-01-14       Impact factor: 3.876

9.  Irisin levels are associated with urotensin II levels in diabetic patients.

Authors:  Wan-Yu He; Qiong Bai; La-Ta A; Chao-Shu Tang; Ai-Hua Zhang
Journal:  J Diabetes Investig       Date:  2015-03-12       Impact factor: 4.232

10.  Irisin Controls Growth, Intracellular Ca2+ Signals, and Mitochondrial Thermogenesis in Cardiomyoblasts.

Authors:  Chao Xie; Yuan Zhang; Tran D N Tran; Hai Wang; Shiwu Li; Eva Vertes George; Haoyang Zhuang; Peilan Zhang; Avi Kandel; Yimu Lai; Dongqi Tang; Westley H Reeves; Henrique Cheng; Yousong Ding; Li-Jun Yang
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.